MiNK Therapeutics Showcases iNKT Cell Therapy Research Efforts
MiNK Therapeutics Highlights Innovative Research at ASCO GI Symposium
NEW YORK — MiNK Therapeutics, Inc. (NASDAQ: INKT), a pioneering clinical-stage biopharmaceutical company, is excited to announce a significant upcoming presentation focused on its groundbreaking iNKT cell therapies aimed at treating cancer. This presentation will take place at the American Society of Clinical Oncology Gastrointestinal Cancers (ASCO GI) Symposium, where attendees will gain insights into the latest advancements in cancer treatment.
Details of the Presentation
The spotlight will be on a Phase 2 study involving agenT-797, a novel iNKT cell therapy, in combination with Agenus' botensilimab and balstilimab. This combination therapy is being evaluated for its effectiveness in patients suffering from refractory gastric cancer, a condition that poses significant treatment challenges.
Key Presentation Information
The presentation's abstract is titled: "A phase II study of agenT-797 (invariant natural killer T-cells), botensilimab (Fc-enhanced CTLA-4 inhibitor), and balstilimab (anti-PD-1) in patients with advanced, refractory gastroesophageal adenocarcinoma." Dr. Samuel Cytryn will present the findings during the Trials in Progress Poster Session A, with the scheduled date and time set for January 23, 2025, from 11:30 AM to 1:00 PM.
What to Expect from the Conference
Attendees can anticipate comprehensive insights into the ongoing research, with complete abstracts being released on January 21, ahead of the symposium. This data will highlight potential advancements in the treatment landscape for patients with this challenging condition.
About MiNK Therapeutics
MiNK Therapeutics stands at the forefront of biopharmaceutical innovation, specializing in the discovery and development of allogeneic invariant natural killer T (iNKT) cell therapies. The company's goal is to provide off-the-shelf, scalable solutions for treating cancer and other immune-mediated diseases. With a robust pipeline that includes both native and next-generation engineered iNKT programs, MiNK is dedicated to changing the current paradigms of cancer treatment.
The Company’s Commitment to Advancement
MiNK's headquarters are situated in New York, NY, where it continues to spearhead research and innovation in the field. The company is committed to maintaining transparency with its investors and the public, routinely updating its website and social media channels with crucial information regarding clinical development, research outcomes, and company news.
Frequently Asked Questions
What is the focus of MiNK Therapeutics at the ASCO GI Symposium?
MiNK Therapeutics will present its research on iNKT cell therapies, specifically the Phase 2 study of agenT-797 for refractory gastric cancer.
When is MiNK Therapeutics' presentation scheduled?
The presentation is scheduled for January 23, 2025, from 11:30 AM to 1:00 PM at the ASCO GI Symposium.
Who will present the findings at the conference?
Dr. Samuel Cytryn will serve as the presenting author for the study on iNKT cell therapy.
What is agenT-797?
agenT-797 is an innovative therapy utilizing invariant natural killer T-cells designed to enhance treatment efficacy in cancer patients.
Where can more information about the company be found?
More details about MiNK Therapeutics and its research can be found on the official website at minktherapeutics.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.